Finance & Capital Markets

  1. Implementing A New CEO Strategy With NervGen's Adam Rogers, M.D. And Rich Macary 4/24/2026

    On this week's episode of the Business of Biotech, we talk with NervGen leaders Adam Rogers, M.D., and Rich Macary about NVG-291, a daily neuroreparative peptide designed to restore function in patients with spinal cord injuries.

  2. Athersys' Ivor Macleod On Bringing Big-League Financial Experience To An Emerging Biotech 8/13/2020

    The Business Of Biotech "Summer Executive Sessions" kick off with a candid conversation with Athersys CFO Ivor Macleod, who brings years of finance leadership at Roche, Merck, and other big pharmas to Athersys as the company readies its lead candidate for life beyond clinical trials. Join us for a discussion on how Macleod is applying big-league finance principles to an emerging biopharma company, and what he's learned about managing funds in a pre-commercial biotech environment.

  3. Strategic Deals With CinRx's Gavin Samuels, M.D. 3/17/2024

    Gavin Samuels, M.D., found his work as an intensive care physician boring. It wasn't until he left the hospital and entered biopharma that he found his footing. Now, he's Chief Business Officer and General Partner at CinRx Pharma, where a deep pipeline of early- to late-stage candidates keeps him on his dealmaking toes. Dr. Samuels' introspective reflections on biotech dealmaking and negotiations plants this episode firmly on the Business of Biotech podcast highlight reel.

  4. The Legend Steve Gorlin's Golden Rules 11/1/2023

    Shortly after Thalidomide became a household word—albeit a very, very bad one—a biotech investor bought it for a couple hundred grand. Who on earth would want a drug pulled from the market for causing birth defects? Steve Gorlin did.

  5. Serial Success With Triumvira's Rob Williamson 3/10/2024

    Rob Williamson's mind and hands have shaped more than 20 biotech startups, leading some to IPO and landing others firmly in Big Bio through acquisition by companies like Merck. Learn secrets to his serial success on this week's Business of Biotech podcast.

  6. Biotech Investing At The Earliest Stages With Santé Ventures' Omar Khalil 8/19/2026

    On this week's episode of the Business of Biotech, Omar Khalil, Managing Director at Santé Ventures, describes forming and funding startups and early-stage biotech companies with a focus on clinical data and differentiation as the key value drivers.

  7. Veteran Advice From The C-Suite With Citius' Leonard Mazur 10/4/2023

    Leonard Mazur has been in the business of biotech for a long, long time, and he has no intention of stopping now. He’s faced challenges won, lost, and ongoing, and he’s willing to share his experiences—from winning FDA approvals to bootstrapping his current effort at Citius Pharmaceuticals—with the transparent confidence of an industry veteran.

  8. Building A Biotech Incubator And Accelerator With Swiss Rockets Founder And CEO Vladimir Cmiljanovic, Ph.D. 8/21/2025

    On this week's episode, ex-handballer Vladimir Cmiljanovic, Ph.D., Founder and CEO at Swiss Rockets, talks about co-discovering bimiralisib with his sister Natasa Cmiljanovic, Ph.D. (and COO at Swiss Rockets), losing his company to a hostile takeover, buying the company back, and building out Swiss Rockets as an incubator with manufacturing capabilities and shared scientific expertise.

  9. True DEI Value in Biopharma with Arcellx's Rami Elghandour 6/16/2024

    Asked about his company’s rapid rise since taking the helm in 2021, Arcellx CEO Rami Elghandour cites a few critical and risky decisions, the execution of some specific people on his all-star team, and a relentless commitment to diversity, equity, and inclusion. Before you skepticize, let me assure you: the man brings receipts.

  10. BoB@JPM: Nima Farzan, Latigo Biotherapeutics 3/19/2025

    In this final installment of our episodes recorded and filmed on-site at the JP Morgan Healthcare Conference, Nima Farzan, CEO of Latigo Biotherapeutics, shares his company's mission to change the pain management paradigm by way of novel, non-opioid medications that target NAV 1.8 sodium channels involved in pain signal transmission.